Compare CBU & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBU | BLLN |
|---|---|---|
| Founded | 1866 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 1994 | N/A |
| Metric | CBU | BLLN |
|---|---|---|
| Price | $62.03 | $73.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $66.67 | ★ $126.71 |
| AVG Volume (30 Days) | 172.0K | ★ 380.2K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 15.41 | N/A |
| EPS | ★ 3.97 | N/A |
| Revenue | ★ $818,007,000.00 | N/A |
| Revenue This Year | $13.46 | $46.29 |
| Revenue Next Year | $7.75 | $30.14 |
| P/E Ratio | $15.96 | ★ N/A |
| Revenue Growth | ★ 9.61 | N/A |
| 52 Week Low | $51.12 | $61.96 |
| 52 Week High | $67.50 | $138.70 |
| Indicator | CBU | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 41.26 |
| Support Level | $60.17 | $64.99 |
| Resistance Level | $64.73 | $83.20 |
| Average True Range (ATR) | 1.28 | 6.48 |
| MACD | 0.01 | -1.05 |
| Stochastic Oscillator | 42.03 | 9.57 |
Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional and governmental customers. The Company also offers comprehensive financial planning, trust administration and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services and Wealth Management Services.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.